Potential universal flu vaccine identified

Image
Press Trust of India Washington
Last Updated : Aug 27 2018 | 10:50 AM IST

Scientists have identified a potential universal influenza vaccine that could protect people against most strains of the virus.

The candidate vaccine, described in the journal Nature Communications, elicited a strong antibody response to a structure on the surface of flu viruses, called the hemagglutinin (HA) stalk.

It protected mice from infection by various flu strains, researchers said.

It has the potential to be developed into a universal flu vaccine, which -- unlike the current seasonal flu vaccines -- could be given a few times over a lifetime to provide protection potentially similar to a tetanus vaccine.

"This vaccine was able to do something that most other candidate flu vaccines have not been able to do," said Drew Weissman, a professor of at the University of Pennsylvania in the US.

"It was able to elicit protective responses against a conserved region that offers broad protection," said Weissman.

"If it works in humans even half as well as it does in mice, then the sky's the limit - it could be something that everyone uses in the future to protect themselves from the flu," said Scott Hensley, an associate professor at University of Pennsylvania in the US.

Modern viral vaccines typically use lab-grown viral proteins to elicit an immune response that protects people against future exposures to a virus. On the whole, this approach has not worked well against influenza viruses.

Seasonal flu vaccines provide incomplete and temporary protection against the flu. This is why they need to be updated every year.

The vaccine does not use flu HA proteins. Instead, it uses mRNA molecules that encode HA proteins to elicit an antibody response.

"When we first started testing this vaccine, we were blown away by the magnitude of the antibody response," said Hensley.

The team observed that after immunisation, these strong antibody responses to the vaccine persisted through the thirty weeks of the experiment.

In addition to the mice, the researchers successfully repeated these experiments in ferrets and rabbits, other species commonly used as vaccine-development animal models.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 27 2018 | 10:50 AM IST

Next Story